Sign in
4

Changes in Ownership

Taysha Gene Therapies, Inc. Filed Acc 0001665124-25-000003

President and Head of R&D sold 370,172 shares at an average $4.58 ($1,695,906)

  • President and Head of R&D acquired 370,172 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Nagendran Sukumar President and Head of R&D 2025-11-28 Option exercise +70,172 $0.70 $49,043 1,076,611 D: show line 1 in the form
Nagendran Sukumar President and Head of R&D 2025-11-28 Option exercise +39,953 $1.71 $68,320 1,116,564 D: show line 2 in the form
Nagendran Sukumar President and Head of R&D 2025-11-28 Sale −110,125 $4.75 $523,094 1,006,439 D: show line 3 in the form
Nagendran Sukumar President and Head of R&D 2025-12-01 Option exercise +260,047 $1.71 $444,680 1,266,486 D: show line 4 in the form
Nagendran Sukumar President and Head of R&D 2025-12-01 Sale −260,047 $4.51 $1,172,812 1,006,439 D: show line 5 in the form
Open-market sales · 370,172 sh · avg $4.58 · $1,695,906

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Nagendran Sukumar President and Head of R&D 2025-11-28 Option exercise · Employee Stock Option (right to buy) −70,172 222,683 D: show line 6 in the form
Nagendran Sukumar President and Head of R&D 2025-11-28 Option exercise · Employee Stock Option (right to buy) −39,953 823,664 D: show line 7 in the form
Nagendran Sukumar President and Head of R&D 2025-12-01 Option exercise · Employee Stock Option (right to buy) −260,047 563,617 D: show line 8 in the form
Loading xslF345X05/form4-12022025_011240.xml…